May 9 2006
MIV Therapeutics, Inc., a leading developer of new generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, provided detailed background in two scientific poster presentations on its advanced, proprietary coating achievements at the prestigious annual international meeting of the Society of Biomaterials held in Pittsburgh, Penn., April 26-27.
At the conference, Dr. Quanzu Yang, Ph.D., a scientist at the University of British Columbia who works under the supervision of Dr. Tom Troczynski, Vice President of Coatings at MIVT, and Mr. Maurice Lien, BSc.Eng., Manager of R&D at MIVI Technologies, a wholly owned subsidiary of MIVT Therapeutics Inc., provided a poster presentation highlighting the Company's latest achievements in developing biopolymer-hydroxyapatite matrix composite coatings. The Company's proprietary composite formulation is designed to protect surrounding tissue from potentially harmful interactions with implanted metallic stents, while also serving as a substrate for next-generation drug-delivery solutions on vascular stents and other devices.
"Participating at the international conference of the Society of Biomaterials was an important opportunity to showcase some of our technology alongside other cutting-edge medical technologies from around the world," said Dr. Troczynski. "The poster presentation was very well-received and helped to increase scientific awareness about the superior biocompatible potential of HAp composite coatings on medical implants. The data on HAp are exciting, and we are committed to bringing this improved coating technology to the market."
MIV Therapeutics is a leader in the research and development of a novel organic material, called Hydroxyapatite (HAp), which is designed to provide medically needed advantages over the current polymer coatings used in the growing, multibillion-dollar worldwide marketplace for vascular stents and other medical devices. In contrast to polymer, HAp is a naturally occurring substance, found in human bone and teeth.
Ongoing studies at MIVT have consistently demonstrated HAp's potential for superior safety and biocompatibility as a coating material on stents and other medical devices. Under the terms of a Collaborative Research Agreement with the University of British Columbia, MIV Therapeutics works closely with UBC to develop HAp medical applications and technologies.